Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

It’s clear there’s a strong connection between sustained earnings growth and hall-of-fame returns. Taking that into account, here are three market-beating stocks that could turbocharge your returns.

e.l.f. Beauty (ELF)

Five-Year Return: +612%

Short for "eyes, lips, face", e.l.f. Beauty (NYSE: ELF) is a developer of high-quality beauty products at accessible price points.

Why Should ELF Be on Your Watchlist?

1. Annual revenue growth of 49.6% over the last three years was superb and indicates its market share is rising
2. Differentiated product offerings are difficult to replicate at scale and result in a best-in-class gross margin of 71%
3. Earnings per share grew by 58.6% annually over the last three years and trumped its peers

e.l.f. Beauty is trading at $118 per share, or 32.9x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

HEICO (HEI)

Five-Year Return: +184%

Founded in 1957, HEICO (NYSE: HEI) manufactures and services aerospace and electronic components for commercial aviation, defense, space, and other industries.

Why Is HEI a Top Pick?

1. Core business can prosper without any help from acquisitions as its organic revenue growth averaged 9.6% over the past two years
2. Earnings per share grew by 25.2% annually over the last two years, massively outpacing its peers
3. HEI is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders

At $299.20 per share, HEICO trades at 64.4x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

Medpace (MEDP)

Five-Year Return: +277%

Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ: MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.

Why Could MEDP Be a Winner?

1. Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 17.8% over the past two years
2. Share buybacks catapulted its annual earnings per share growth to 35.1%, which outperformed its revenue gains over the last five years
3. Improving returns on capital reflect management’s ability to monetize investments

Medpace’s stock price of $305.90 implies a valuation ratio of 24.5x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.